Royalty Pharma plc has completed the acquisition of its external manager, RP Management, LLC, marking a significant milestone for the company. This transaction, which received 99.9% shareholder approval, transitions Royalty Pharma from an external management model to an internalized structure. All employees of RP Management have now become employees of Royalty Pharma. This move is expected to enhance shareholder value through improved governance and reduced costs, while better positioning the company to support innovation in the life sciences industry. Royalty Pharma will update its full-year 2025 guidance to reflect this change when it reports its second quarter 2025 financial results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.